Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5526 - longitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC)

Date

11 Sep 2017

Session

Poster display session

Presenters

Reza Elaidi

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

R. Elaidi1, D. Helley2, L. Mauge2, C. Badoual3, E. Tartour4, E. Braychenko5, L. Albiges6, B. Escudier7, S. Oudard8

Author affiliations

  • 1 Medical Oncology - Hôpital Européen Georges Pompidou, ARTIC, 75015 - Paris/FR
  • 2 Biologic Haematology, Hopital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75015 - Paris/FR
  • 3 Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 4 Biologic Immunology, Hopital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75015 - Paris/FR
  • 5 Medical Oncology, ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, 75015 - Paris/FR
  • 6 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 7 Medical Oncology, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 8 Immunothérapie Et Traitement Antiangiogénique En Pathologie cancérologique, Hopital European George Pompidou, 75015 - Paris/FR
More

Resources

Abstract 5526

Background

If many drugs are available in RCC, we lack predictive biomarkers of disease recurrence or progression for personalized treatment. Circulating biomarkers (CB) are attractive candidates for disease monitoring. Longitudinal assessment of CB was performed in the NEORAD clinical trial (NCT01715935).

Methods

Locally advanced (LA) and metastatic (M) patients with clear cell or papillary RCC received 6 weeks prior-nephrectomy everolimus (Ev). CB assessed were: angiogenesis factors: VEGF-A, VEGFR-1&2, bFGF, SDF1, PlGF; CEC; CTC; HSC; immune cells: CD45, CD14+VEGFR-1/Tie2, Treg, IL-6. Clinical/histological (CH): ECOG-PS, tumor burden (TB), % necrosis, % sarcomatoid. Exploratory analysis (EA): CB and CH (prior to Ev, D22, D42, 4 weeks post-nephrectomy (+ 4 weeks if Ev resumed in M pts) in PD vs non-PD pts used Bayesian Model Averaging (BMA) and regularized Cox regression (LASSO). Three modeling strategies were compared for robustness.

Results

25 patients were included: LA = 14, M = 11. In LA and M cohorts, respectively 2 and 9 pts exhibited progression during the 12m post-surgery follow-up period. Most important predictors upon EA (by order): tumor burden, VEGF-A, LA/M, VEGFR-2, % necrosis, IL-6, VEGFR-1, age, PlGF. Higher TB at baseline and % necrosis were associated with increased risk of 6m post-nephrectomy progression. TB, IL-6, VEGF-A, VEGFR-1&2 exhibited nonlinear relationships suggesting complex underlying pathophysiological mechanisms involved in response to Ev, and are currently explored. Reduced VEGFR-2 at D42 was associated with worse PFS in both cohorts. Upon BMA and LASSO, % necrosis and TB were among the most retrieved predictors prior to nephrectomy, whereas CD45 and CD34 + 45-146+ at 4 weeks post-nephrectomy were the best CB predictors. No significant change in monocyte populations and in Treg was observed.

Conclusions

VEGF related CB, TB and % necrosis were the best candidates to discriminate PD- vs non-PD in LA and M pts. Extensive analysis of data collected using robust non-linear models could contribute to improve our understanding of mechanisms involved and suggest predictive biomarkers to be validated.

Clinical trial identification

NCT01715935

Legal entity responsible for the study

ARTIC

Funding

Novartis

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.